The agreement is for Desidustat, a novel oral HIF-PH inhibitor for the treatment of anemia in patients with Chronic Kidney Disease (CKD) not-on-dialysis and for the treatment of anemia CKD patients on dialysis in Greater China, Zydus said in a statement. "Under the license agreement, CMS will pay Zydus an initial upfront payment," it added.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/36gl8IF
via IFTTT
0 comments:
Post a Comment